Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Prospective Cohort Study on Long-term Effective and Safe Use of Pegunigalsidase Alfa in Adult Fabry Patients Under "Real-world" Setting

NCT07109375 is registered in ClinicalTrials.gov with Chiesi Italia as lead sponsor.

NCT NCT07109375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07109375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Prospective Cohort Study on Long-term Effective and Safe Use of Pegunigalsidase Alfa in Adult Fabry Patients Under "Real-world" Setting
Lead sponsor
Chiesi Italia
Phase
Observational
Overall status
Recruiting
Start date
June 15, 2026
Completion date
February 28, 2029
Enrollment
75 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease